Epcoritamab in Previously Treated WM — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Epcoritamab in Previously Treated WM — Stella

Home/Waldenstrom Macroglobulinemia/

View on ClinicalTrials.gov

Recruiting

Back to Waldenstrom Macroglobulinemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Key details

Phase

Safety & dosing

Sponsor

Gottfried von Keudell, MD PhD

Collaborators

Genmab

Enrollment target

~20 participants

Started

December 2024

Primary completion

April 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.